BioSpace News Archive

ValGenesis, Inc., the market leader in enterprise validation lifecycle management systems, and Radiant Digital PTE Ltd. a provider of digital transformation delivery services to commercial and government clients, have partnered to facilitate the digital transformation of life sciences companies in Singapore.

Non-small cell lung cancer is one of the most common and aggressive forms of cancer. Researchers have been exploring effective treatments to improve the survival rates of patients with NSCLC, such as by targeting the immune cells in the tumor microenvironment.

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced upcoming presentations by the Company and collaborators at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, to be held June 24 – 27, 2023, in Chicago, Ill.

Owlet (NYSE: OWLT, “the Company”), the pioneer of smart baby monitoring, announces clearance from the U.S. Food and Drug Administration (“FDA”) of BabySat™ , the first medical pulse-oximetry device featuring its advanced, wire-free sock design.

Veracyte, Inc. (Nasdaq: VCYT) announced that new data presented at ENDO 2023, the annual meeting of The Endocrine Society, suggest the company’s Afirma molecular testing and whole-transcriptome capabilities can provide novel insights that may advance the scientific understanding of thyroid nodule biology.

Seagen Inc. (NASDAQ: SGEN) today announced that the clinical research cooperative German Hodgkin Study Group (GHSG) presented results showing that a phase 3 trial of ADCETRIS® in combination with chemotherapy.

RenovoRx, Inc today announced the appointment of Margaret A. Tempero, M.D., Director, UCSF Pancreas Center and Leader of the UCSF Pancreas Cancer Program, to the Company’s Scientific Advisory Board (SAB).

Jaguar Health, Inc. (Nasdaq:JAGX) today announced that Napo Pharmaceuticals, Jaguar’s wholly owned subsidiary, is now a Corporate Partner of the Multinational Association of Supportive Care in Cancer (MASCC).

Devonian Health Group Inc. is pleased to announce that the United States Patent and Trademark Office (“USPTO”) issued a Notice of Allowance for Devonian’s Patent application No.: 16/998.004 entitled “Thylakoid Extract Composition and Formulation for the Treatment of Inflammatory Bowel Disease”.

Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA ® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting.